EGRIFTA SV^® is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Download EGRIFTA SV^®
Enrollment Form

Call THERA Patient Support^® - 1-833-23THERA (1-833-238-4372) – Mon-Fri 8:30 a.m. – 8 p.m. EST

HELP YOUR PATIENTS RELIEVE THE BURDEN OF EXCESS VISCERAL ABDOMINAL FAT

Help Curb Excess Visceral Abdominal Fat

EGRIFTA SV^®: The only once-daily subcutaneous injection with a small volume of administration.

Concentrated strength, dosed in a single vial
Injection volume of only 0.35 mL
Small needle size (½” 30-gauge needle)
Store at room temperature (no refrigeration required)

The only FDA approved treatment* indicated for the treatment of excess visceral abdominal fat in HIV-infected adult patients with lipodystrophy

Proven to significantly reduce excess abdominal fat.

EGRIFTA SV^® is not indicated for weight loss management.

See the Results

How does EGRIFTA SV^® work?

It stimulates the body's own pulsatile release of growth hormone.

Learn about the mechanism of action

Get your patients started and staying on therapy

THERA patient support^® offers comprehensive services and personal support for you and your patients.

Find out more

*An approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.